6JU0 Stock Chart & Stats
€0.28
€0.00(0.00%)
At close: 4:00 PM EDT
€0.28
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.46M
Enterprise Value€11.17
Total Cash (Recent Filing)€4.12M
Total Debt (Recent Filing)€293.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 11, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding15,138,782
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.45Price Target Upside7559.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Helix Regulatory ProgressFinal FDA meeting minutes ratify the Helix pre-submission feedback and support a follow-on De Novo path. Independent clearance could make the catheter an enabling platform for cell, gene and protein therapies, broadening partnership and commercialization options.
CardiAMP Japan Approval PathPMDA consultation supports a Shonin submission after addressing defined documentation and study requirements. Japanese approval would create an initial commercial route for CardiAMP and provide a reference market for broader expansion, although execution remains necessary.
Improved Cost ControlLower operating and R&D expenses indicate improving cost discipline and could extend available resources for regulatory and clinical work. Sustained control would reduce the funding burden, though the company remains pre-commercial and loss-making.
Bears Say
No Meaningful RevenueThe absence of meaningful revenue shows that BioCardia has not yet established a commercial business model. Continued operating and gross losses leave results dependent on successful clinical development, regulatory approval and eventual reimbursement.
Cash Burn And Dilution RiskPersistent negative operating and free cash flow means BioCardia cannot currently fund development internally. Further equity financing may be needed to accelerate trials, creating dilution risk and making progress dependent on continued capital access.
Slow Clinical EnrollmentSlow, resource-dependent enrollment can extend the timeline to confirmatory evidence and regulatory decisions. Delays would defer potential commercialization while increasing development costs, financing needs and the risk that the program loses momentum.
BioCardia News
6JU0 FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was €0.28 and its highest was €0.32 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is €15.46M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Aug 12, 2026. The company reported -€0.113 earnings per share for the quarter, beating the consensus estimate of -€0.156 by €0.043.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.11.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 15,138,782 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -€0.113 in its last earnings report, beating expectations of -€0.156. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in DE:6JU0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCardia Inc
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
6JU0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful regulatory progress across Japan (PMDA) and the U.S. (FDA) and favorable feedback for the HELIX catheter, supported by substantial clinical experience (~500 Helix patients, >20x procedural experience vs peers). Financially, the company improved expense control and narrowed net losses, and raised ~$4.9M, leaving cash into 2027. Key challenges include additional PMDA documentation requests, relatively slow enrollment in the U.S. confirmatory trial that is resource-constrained, tight near-term financing needs to accelerate enrollment, and some regulatory process uncertainties (FDA minutes delay, endpoint discussions, reimbursement timing). On balance, positives (regulatory momentum, commercialization pathway in Japan, improved financial trends) materially outweigh the operational and cash runway challenges, though execution risk remains.View all DE:6JU0 earnings summaries6JU0 Stock 12 Month Forecast
Average Price Target
€21.45
▲(7559.01% Upside)
Technical Analysis
Pluri
―
Celularity
―
Revelation Biosciences
―
SeaStar Medical Holding
―
Cardio Diagnostics Holdings
―